Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of MP03-36 and MP03-33 in Children With Perennial Allergic Rhinitis
NCT01018862Phase 3Completed
- Sponsor
- Meda
- Start
- Nov 2009
- Primary completion
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of azelastine in perennial allergic rhinitis (PAR) (3 arms), sponsored by Meda. Primary endpoint: Total Nasal Symptom Score at 28 days. Started Nov 2009; status: completed.
02
Drugs
azelastine
03
Conditions
perennial allergic rhinitis (PAR)
Beyond the preview
Go deeper on NCT01018862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01018862.